Sugar Mimetics: Why and How

Pierre Vogel*

Keywords: COST · Sugar mimetics

Besides their role in energy storage, carbohydrates contribute to the structural framework of cells and tissues. Conjugates with proteins (glycoproteins) or lipids (glycolipids) are the words, the phrases used in cell–cell and cell–pathogen communications [1]. Cell-surface oligosaccharides control cell adhesion, fertilization, inflammation, the immune responses and metastasis. Their biosynthesis implies sequences of reactions catalyzed by glycosyltransferases (enzymes that catalyze the glycosidation of sugars or of other substrates) and glycosidases (enzymes that catalyze the cleavage of mono-, disaccharides or oligosaccharides from larger oligosaccharides) [2]. Inhibitors of these enzymes are potential antibacterial, antiviral, antimetastatic, antidiabetes, antihyperglycemic, antiadhesive, or immunostimulatory agents [3]. Sugar (monosaccharide, disaccharide, oligosaccharide) mimetics can be such inhibitors. Furthermore, they are tools to study the mechanisms of cellular interactions, the biosynthesis of glycoproteins and glycolipids, the catabolism of glyconjugates [3], and the mechanisms of digestion [4].

Monosaccharide Mimetics

Pyranose and furanose analogues, in which nitrogen replaces oxygen in the ring (imino-sugars), are inhibitors of glycosidases. In vivo they are N-protonated and thus imitate in terms of charge and shape the transition structures, or the intermediates that follow, of the glycosidase-catalyzed hydrolyses of O-glycosides. These compounds have been found in Nature [5]. For instance, 1-deoxynojirimycin (1), an α-glucosidase I inhibitor, inhibits syncytia formation with HIV1 [6]. Its n-butyl derivative (2) prevents Tay-Sachs disease [7], it reduces human hepatitis B [8] and retards HIV entry [9]. Castanospermine (3), a natural α-glucosidase inhibitor has a synergic effect with AZT in inhibiting HIV1 and HIV2 growth [10]. It also prolongs renal allograft survival in rats [11]. Swainsonine (4), another indolizidine found in Nature, contains an iminofuranoside moiety. It is a α-mannosidase II inhibitor that blocks Golgi oligosaccharide processing. Clinical trials have shown that 4 reduces solid tumors and hematological malignancies [12] (Scheme 1).

Starting from our ‘naked sugars of the first generation’ (e.g. 5, 6 obtained by Diels-Alder addition of furan to enantiomerically pure 1-cyanovinyl esters [13]), we have prepared the first examples of pentahydroxyindolizidines [14]. Derivative 7, like swainsonine (4), is a potent inhibitor of α-mannosidase but, unlike 4, does not inhibit other glucosidases [15]. Applying the same methodology, we have prepared for the first time allononojirimycin (8) [16] and analogue 9 (Scheme 1).

Pyranose and furanose analogues, in which carbon replaces oxygen in the ring (carba-sugars), can have interesting biological activities. Natural derivatives such as the pericosines A (10) and B (11) are antitumor agents [18]. Cyclopellitol (12) and its synthetic stereomers are glycosidase inhibitors [19]. Synthetic carba-sugars are potential leads in all kinds of therapeutic application. For instance, the potent neuraminidase inhibitor GS4071 (13) is an active drug (administered by nasal spray) for the treatment and prophylaxis of influenza infection [20]. The ‘naked sugar’ methodology has been applied to prepare 12 [21] and other carba-sugars such as 14, a new orally active venous antithrombotic agent [22]. Its advantage is that it is more resistant toward in vivo hydrolysis than the corresponding O- or S-xylosides.
Disaccharide Mimetics

Monosaccharide mimetics often inhibit more than one enzyme in vivo. Selectivity should be increased if the imino-sugar included not only the steric and charge information of the glycosyl moiety, which is liberated during the glycosidase-catalyzed hydrolysis, but also that of the aglycon which is attached to it. Such inhibitors could be dideoxy-imino-alditols linked to other sugars through non-hydrolyzable links such as in the C-linked imino-disaccharides. These disaccharide mimetics could also be candidates as haptons for the generation of catalytic antibodies [23]. The comparison of inhibitory activities toward glucoamylase between acarbose (a tetrasaccharide mimic of the non-reducing end of amylose, \( K_i = 10^{-12} \text{ M} \) [24]) and (+)-lentiginosine, a 1,2-dihydroxyindolizidine; \( K_i = 10^{-6} \text{ M} \) [25]) demonstrates that inhibition is greatly enhanced if the glycosyl-cation mimic is attached to a mimetic of the aglycon, the compound from which a monosaccharide is cleaved. Linking isofagomine and methyl \( \alpha\)-D-glycopyranoside generates a better glucoamylase inhibitor than isofagomine [26]. The first example of a C-linked imino-disaccharide (1,5-dideoxy-1,5-D-mannitol linked at C(6) of D-galactose through a CH₂ unit) was prepared by Johnson and co-workers [27]. Other examples of 'linear' C-linked imino-disaccharides were obtained by the groups of Martin [28] and Van Boom [29]. We have prepared the first examples of 'branched' C-linked imino-disaccharides [30] [31]. Further examples were reported by Johnson and co-workers [32] and by our group [33] [34]. Brandi and co-workers [35] have obtained the first examples of (1→2)-linked pseudo imino-C-disaccharides in which 2,3-dihydroxyprorolidine or 2-hydroxyprorolidine is linked at C2 and α-glucose via a single C=C bond. Robina and our group have been working on the synthesis of homo-(1→3)-C-linked imino-disaccharides in which an imino-sugar is attached to another sugar through a two-carbon linker [36]. We have found that 15, a pyrrolidine-3,4-diol attached at C(3) of galactose via a hydroxymethylene linker is a weak, but specific inhibitor of Jack bean a-mannosidase [31]. Derivative 16 is an anti-leukemic agent [37]. Compound 17 is a moderate inhibitor of \( \alpha\)-L-fucosidase from bovine liver (\( K_i = 100 \text{ M} \)) [34]. The neutral C-disaccharide 18 (\( \alpha\)-D-ManpCH₂(1→3)-D-GalNac) inhibits β-galactosidase from Jack bean (\( IC_{50} = 9.4 \mu\text{M}, K_i = 7.5 \mu\text{M} \)) [38], demonstrating for the first time that C-disaccharides that do not incorporate an imino-sugar or an aminocyclitol can be potent glycosidase inhibitors. The C-disaccharide 18 is also an inhibitor of human \( \alpha\)-L,3-fucosyltransferase VI [39]. The C-linked disaccharides 15–18 were derived from our 'naked sugar (first generation') [40]. The methods are highly stereoselective but require several steps. We are developing [41] new approaches to the synthesis of C(1→3)-disaccharides and analogues based on the cross-aldolization of aldehydes 21, derived from monosaccharides or azasugars, with enolates 20 obtained by nucleophilic addition of isolevoglucosenone (19), an enone derived from D-glucose in four steps [42]. In principle, libraries of aldols 22 can be obtained in one or two steps. Stereoselective reductions of 22, alcoholysis and deprotection provides the corresponding C-disaccharides 23 or 24 [41] (Scheme 2). Quenching enolates 20 as triflates 25, followed by Nozaki-Kishi couplings with aldehydes 21 generate the corresponding eno-C-disaccharides 26, the hydroboration of which and deprotection produces the corresponding C(1→4)-disaccharides 27. Similarly, starting from levoglucosenone, the product of cellulose pyrolysis, the same method allows the generation of C(1→2)-disaccharides 30 (Scheme 3). Thus libraries of C(1→2), C(1→3),
C(1→4)-disaccharides can be obtained starting with the same sublibraries of enones (19, 28), nucleophiles (MNu) and aldehydes (21) [43].

For the synthesis of C(1→1)-disaccharides, the carboxylative Stille condensation of stannylated glycal and iodo glycal derivatives 32 is the shortest and most flexible approach we have to propose [44] (Scheme 4).

We are grateful to the Swiss National Science Foundation for financial support. We thank the COST D13 program (project COSTD13/0001/99) for encouragement.

[1] See e.g.: A. Varki, Glycobiology 1993, 3, 97; P.R. Crocker, T. Feizi, Curr. Opin. Struct. Bio. 1996, 6, 679; P. Sears, C.-H. Wong, Angew. Chem. Int. Ed. 1999, 38, 2300.

[2] R. Kornfeld, S. Kornfeld, Annu. Rev. Biochem. 1985, 54, 631.

[3] A. Lal, P. Pang, S. Kalekar, P.A. Romero, S. Herscovics, K.W. Moremen, Glycobiology 1998, 8, 981 and references cited therein.

[4] D.D. Schmidt, W. Frommer, B. Junge, L. Muller, W. Wingender, E. Tausche, D. Schefer, Naturwissenschaften 1977, 64, 535.

[5] a) M.S.J. Simmonds, G.C. Kite, E.A. Porter, in ‘Iminosugars as Glycosidase Inhibitors, Nojirimycin and Beyond’, Ed. A.E. StUtz, pp. 8-30; b) For recent insights into the mechanisms of glycosidas inhibition see: T.D. Angew. Chem. Int. Ed. 1999, 38, 750.

[6] See e.g.: R. Pal, G.M. Hoke, M.G. Samadasharan, Proc. Natl. Acad. Sci. USA 1989, 86, 3384.

[7] F.M. Platt, G. Reinkenmeier, R.A. Dwek, T.D. Butters, J. Biol. Chem. 1997, 272, 19656; T. Kolter, Angew. Chem. Int. Ed. Engl. 1997, 36, 1955.

[8] A. Mehta, K.T. Lu, T.M. Block, B.S. Blumberg, R.A. Dwek, Proc. Natl. Acad. Sci. USA 1997, 94, 1822.

[9] P.B. Fischer, G.B. Karlsson, R.A. Dwek, F.M. Platt, J. Virology 1996, 70,1753; E. Fenouillet, M.J. Papandreou, J.M. Jones, Virology 1997, 231, 89.

[10] See e.g.: V.A. Johnson, B.D. Walker, M.A. Barlow, T.J. Paradis, T.C. Chou, M.S. Hirsch, Antimicrob. Agents Chemother 1989, 33, 53.

[11] See e.g.: P.M. Grochowicz, A.D. Hibberd, K.M. Bowen, D.A. Clark, W.D. Cowden, C.R. Paris, D.O. Wittenborg, Transplantation Proc. 1990, 22, 2117.

[12] See e.g.: P.E. Gross, J. Baptiste, B. Fernandes, M. Baker, J.W. Dennis, Cancer Res. 1994, 54, 1450.

[13] P. Vogel, D. Fattori, F. Gasparini, C. Le Drian, Synlett 1990, 1, 173; J.L. Reymond, P. Vogel, Tetrahedron: Asymmetry 1999, 10, 567.

[14] Y. Chen, P. Vogel, J. Org. Chem. 1994, 59, 2487.

[15] S. Picasso, Y. Chen, P. Vogel, Carbohydr. Lett. 1994, 1, 1.

[16] Y. Auberson, P. Vogel, Angew. Chem. 1989, 101, 1554.

[17] J. Wagner, P. Vogel, Tetrahedron 1991, 47, 9641.

[18] C. Schuller, P. Vogel, V. Jager, Carbohydr. Res. 1998, 314, 25; A. Numate, M. Iritani, T. Yamada, K. Minoura, E. Matsumura, T. Yamori, T. Tsuuro, Tetrahedron Lett. 1997, 38, 8215.

[19] S. Atsumi, H. Iimura, C. Nosaka, K. Umezawa, J. Antibiot. 1990, 43, 1579; K. Tatsuta, Y. Niwata, K. Umezawa, K. Toshima, M. Nakata, J. Antibiot. 1991, 44, 912.

[20] M. von Itzstein, J.C. Dyason, S.W. Oliver, H.F. White, W.Y. Wu, G.B. Kok, M.S. Pegg, J. Med. Chem. 1996, 39, 388; C.U. Kim, W.L. Lin, M.A. Williams, H. Hu, L. Zhang, C.X.P.A. Escare, D.B. Mendel, W.G. Laver, R.C. Stevens, J. Med. Chem. 1998, 41, 2451.

[21] V. Moritz, P. Vogel, Tetrahedron Lett. 1992, 33, 5243.

[22] V. Jeanneret, P. Vogel, P. Renaut, J. Millet, J. Theveniaux, V. Barberousse, Bioorg. Med. Chem. Lett. 1998, 8, 1687; P. Renaut, J. Millet, C. Sepachle, J. Theveniaux, V. Barberousse, V. Jeanneret, P. Vogel, Helv. Chim. Acta 1998, 81, 2043.

[23] See e.g.: P.D. Rye, N.V. Bovin, E.V. Vlasova, R.A. Walker, Glycobiology 1995, 5, 385.

[24] I. Pastuszak, R.J. Molyneux, L.F. James, A.D. Elbein, A.R. Walker, Biochemistry 1990, 29, 1886.